drugset / Trial / NCT05671913

Scheduled Intranasal Ketamine

NCT05671913

Phase 0 Withdrawn Sanford Health
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this research is to determine if scheduled intranasal ketamine effects opioid requirements in adult trauma patients with moderate to severe pain in the inpatient setting.

Timeline

Start
2023-01-01
Primary completion
2025-12-31
Completion
2026-01-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule Intranasal

Indications

No indication recorded.